Andrew Centea
About Andrew Centea
Andrew Centea is a Product Manager for Melanoma at Bristol Myers Squibb in Montreal, Quebec, Canada, with a diverse background in oncology, sales, marketing, and project management.
Current Role at Bristol Myers Squibb
Andrew Centea is currently serving as the Product Manager for Melanoma at Bristol Myers Squibb. Based in Montreal, Quebec, Canada, he focuses on developing and executing product strategies for the melanoma segment. His work is integral in advancing the company's immuno-oncology initiatives.
Previous Experience at AstraZeneca
Andrew Centea worked as the Capability Development Manager, Oncology at AstraZeneca. He held this position from 2018 to 2020 in Toronto, Ontario, Canada. During his tenure, he was instrumental in enhancing the oncology capabilities of the company through training and development programs.
Professional Journey at Bristol-Myers Squibb
Before his current role, Andrew Centea was Key Account Manager, Immuno-Oncology at Bristol-Myers Squibb from 2015 to 2018. Located in the Vancouver, Canada Area, he managed key accounts and focused on promoting immuno-oncology products such as OPVIDO and YERVOY, with a particular emphasis on metastatic and adjuvant melanoma.
Educational Background
Andrew Centea holds an MBA Co-op with a focus on Strategic Marketing and Entrepreneurship from McMaster University, where he studied from 2009 to 2011. He also achieved a B.Sc. in Honours Biomedical Sciences from the University of Waterloo, completing his studies from 2003 to 2007. His academic background has equipped him with a robust foundation in both science and business.
Early Career at Germiphene Corporation
Andrew Centea started his professional journey at Germiphene Corporation, where he held multiple roles from 2005 to 2009. His positions included Microbiologist Assistant, Quality Control Analyst, R&D Associate, R&D Project Coordinator, and Project Manager. These roles provided him with extensive experience in research and development, as well as project management.